The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Assessment of sacituzumab govitecan (SG) in patients with prior neoadjuvant/adjuvant chemotherapy in the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC).
 
Lisa A. Carey
Research Funding - Abbvie (Inst); Immunomedics (Inst); NanoString Technologies (Inst); Novartis (Inst); Seagen (Inst); Syndax (Inst); Veracyte (Inst)
Patents, Royalties, Other Intellectual Property - Royalty-sharing agreement, investorship interest in licensed IP to startup company, Falcon Therapeutics, that is designing neural stem cell-based therapy for glioblastoma multiforme. (I)
(OPTIONAL) Uncompensated Relationships - Aptitude Health (Inst); AstraZeneca/Daiichi Sankyo (Inst); Exact Sciences (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Sanofi (Inst)
 
Delphine Loirat
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Immunomedics; MSD Oncology; Novartis; Pfizer; Roche
Expert Testimony - Amgen; Roche
Travel, Accommodations, Expenses - AstraZeneca; MSD; Pfizer; Roche
 
Kevin Punie
Honoraria - Lilly (Inst); Lilly (Inst); Mundipharma (Inst); Novartis (Inst); Pfizer; Pfizer (Inst); Pfizer (Inst); Roche (Inst)
Consulting or Advisory Role - AstraZeneca (Inst); Lilly (Inst); Lilly (Inst); Novartis; Novartis; Novartis; Novartis (Inst); Novartis (Inst); Novartis (Inst); Pierre Fabre (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Teva (Inst); Vifor Pharma (Inst)
Research Funding - Sanofi (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Novartis; Pfizer; PharmaMar; Roche; Roche; Roche; Roche
 
Aditya Bardia
Consulting or Advisory Role - bioTheranostics; Daiichi Sankyo/Astra Zeneca; Foundation Medicine; Genentech; Genentech/Roche (Inst); Immunomedics; Immunomedics (Inst); Innocrin Pharma (Inst); Merck; Novartis; Novartis (Inst); Pfizer; Pfizer (Inst); Philips Healthcare; Puma Biotechnology; Radius Health; Radius Health (Inst); Sanofi; Spectrum Pharmaceuticals
Research Funding - AstraZeneca/Daiichi Sankyo (Inst); Genentech (Inst); Immunomedics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Radius Health (Inst); Sanofi (Inst)
 
Veronique Dieras
Honoraria - Abbvie; AstraZeneca; Daiichi Sankyo; Eisai; Lilly; MSD; Novartis; Pfizer; Roche/Genentech; Seagen
Consulting or Advisory Role - Abbvie; AstraZeneca; Daiichi Sankyo; Eisai; Lilly; MSD; Novartis; Pfizer; Roche/Genentech; Seagen
Speakers' Bureau - AstraZeneca; Daiichi Sankyo; Lilly; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Lilly; Novartis; Pfizer; Roche
 
Florence Dalenc
No Relationships to Disclose
 
Jennifer Robinson Diamond
Consulting or Advisory Role - immunomedics
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Deciphera (Inst); Immunomedics (Inst); MedImmune (Inst); Merck (Inst); Millennium (Inst); OnKure (Inst); Rexahn Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Medimmune
 
Christel Fontaine
No Relationships to Disclose
 
Grace Wang
Research Funding - Daiichi Sankyo (Inst); Eisai (Inst); Lilly (Inst); Pharmacyclics (Inst); Seagen (Inst)
 
Hope S. Rugo
Honoraria - Mylan; Puma Biotechnology
Consulting or Advisory Role - Samsung
Research Funding - AstraZeneca (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Genentech (Inst); Immunomedics (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Novartis (Inst); OBI Pharma (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - AstraZeneca Spain; Daiichi Sankyo; Macrogenics; Merck; Mylan; Novartis; Pfizer
 
Sara A. Hurvitz
Stock and Other Ownership Interests - Ideal Implant (I); ROM Tech (I)
Research Funding - Ambryx (Inst); Amgen (Inst); Arvinas (Inst); Bayer (Inst); Biomarin (Inst); Cascadian Therapeutics (Inst); Daiichi Sankyo (Inst); Dignitana (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Lilly (Inst); Macrogenics (Inst); Merrimack (Inst); Novartis (Inst); OBI Pharma (Inst); Pfizer (Inst); Phoenix Molecular Designs (Inst); Pieris Pharmaceuticals (Inst); Puma Biotechnology (Inst); Radius Health (Inst); sanofi (Inst); Seagen (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Lilly
Other Relationship - Pfizer; Roche
 
Kevin Kalinsky
Stock and Other Ownership Interests - Array BioPharma (I); GRAIL (I); Pfizer (I)
Consulting or Advisory Role - AstraZeneca; bioTheranostics; Cyclacel; Eisai; Genentech/Roche; immunomedics; Ipsen; Lilly; Merck; Novartis; Oncosec; pfizer; Seagen
Speakers' Bureau - Lilly
Research Funding - Acetylon Pharmaceuticals (Inst); Amgen (Inst); Calithera Biosciences (Inst); CytomX Therapeutics (Inst); Genentech/Roche (Inst); Immunomedics (Inst); incyte (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Seagen (Inst); Zeno Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Lilly; Pfizer
Other Relationship - Genentech; Immunomedics
 
Joyce O'Shaughnessy
Honoraria - Abbvie; Agendia; Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Eisai; Genentech; Genomic Health; GRAIL; HERON; Immunomedics; Ipsen; Jounce Therapeutics; Lilly; Merck; Myriad Pharmaceuticals; Novartis; Odonate Therapeutics; Pfizer; Puma Biotechnology; Roche; Samsung; Sanofi; Seagen; Syndax
Consulting or Advisory Role - Abbvie; Agendia; Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Eisai; Genentech; Genomic Health; GRAIL; HERON; Immunomedics; Ipsen; Jounce Therapeutics; Lilly; Merck; Myriad Pharmaceuticals; Novartis; Odonate Therapeutics; Pfizer; Puma Biotechnology; Roche; Samsung; Sanofi; Seagen; Syndax
Speakers' Bureau - AstraZeneca; Lilly; Novartis; Pfizer; Pfizer
Research Funding - Seagen (Inst)
Travel, Accommodations, Expenses - Abbvie; Agendia; Amgen; AstraZeneca; Celgene; Eisai; Genomic Health; GRAIL; Ipsen; Jounce Therapeutics; Lilly; Myriad Pharmaceuticals; Novartis; Pfizer; Puma Biotechnology; Roche; Sanofi; Seagen
 
Sibylle Loibl
Honoraria - Chugai Pharma
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo (Inst); EirGenix (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Lilly (Inst); Medscape (Inst); Merck KGaA (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Puma Biotechnology (Inst); Roche (Inst); Samsung (Inst); Seagen (Inst)
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Immunomedics (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Patent Pending EP14153692.0 (Inst)
 
Luca Gianni
Consulting or Advisory Role - ADC Therapeutics; AMGEN; AstraZeneca; BioMedical Insights; Celgene; Forty Seven; G1 Therapeutics; Genenta Science; Genentech; Genomic Health; Lilly; Menarini; Merck Sharp & Dohme; METIS Precision Medicine; Novartis; Odonate Therapeutics; Oncolytics; Onkaido Therapeutics; Pfizer; Revolution Medicines; Roche; Sandoz; Sanofi; Seagen; Synaffix; Synthon; Taiho Pharmaceutical; Zymeworks
Research Funding - Revolution Medicines (Inst); Zymeworks (Inst)
Patents, Royalties, Other Intellectual Property - Roche
Travel, Accommodations, Expenses - Celgene; Chugai Pharma; Pfizer; Roche
 
Martine J. Piccart-Gebhart
Consulting or Advisory Role - AstraZeneca; Camel-IDS; Debiopharm Group; Immunomedics; Immutep; Lilly; Menarini; MSD; Novartis; Odonate Therapeutics; Pfizer; Roche/Genentech; Seagen
Research Funding - AstraZeneca (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Radius Health (Inst); Roche/Genentech (Inst); Servier (Inst); Synthon (Inst)
Other Relationship - EU Cancer Mission Board; Oncolytics
 
Quan Hong
Employment - Gilead Sciences; Gilead Sciences; Immunomedics
Leadership - Immunomedics
Stock and Other Ownership Interests - Immunomedics
 
Martin Sebastian Olivo
Employment - Immunomedics/Gilead
Leadership - Immunomedics/Gilead
Stock and Other Ownership Interests - Immunomedics/Gilead
Travel, Accommodations, Expenses - Immunomedics/Gilead
 
Loretta Itri
Employment - Immunomedics
Leadership - Immunomedics
Stock and Other Ownership Interests - Immunomedics
Consulting or Advisory Role - Immunomedics
Travel, Accommodations, Expenses - Immunomedics
 
Javier Cortes
Stock and Other Ownership Interests - MedSIR
Honoraria - Celgene; Daiichi Sankyo; Eisai; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Samsung
Consulting or Advisory Role - AstraZeneca; Athenex; Bioasis; Biothera; Boehringer Ingelheim; Celgene; Cellestia Biotech; Clovis Oncology; Daiichi Sankyo; ERYTECH Pharma; GlaxoSmithKline; Kyowa Kyrin; Leuko; Lilly; Merck Sharp & Dohme; Merus; Polyphor; Roche; Seagen; SERVIER
Research Funding - ARIAD (Inst); AstraZeneca (Inst); Baxalta (Inst); Bayer (Inst); Eisai (Inst); Guardant Health (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Piqur (Inst); Puma Biotechnology (Inst); Queen Mary university of London (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo; Eisai; Novartis; Pfizer; Roche